Literature DB >> 24968706

Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls.

Inge De Wandele1, Patrick Calders2, Wim Peersman3, Steven Rimbaut4, Tine De Backer5, Fransiska Malfait6, Anne De Paepe6, Lies Rombaut3.   

Abstract

AIM: This study provides insight into the profile and importance of autonomic symptoms in the hypermobility type (HT) of Ehlers-Danlos syndrome (EDS). The impact of these symptoms is put into perspective by comparing with fibromyalgia (FM) and two other EDS types.
METHODS: Overall, 80 patients with EDS-HT participated, as well as 11 with classical EDS (cEDS), seven with vascular EDS (vEDS), 38 with FM, and 43 healthy controls. All participants filled out the autonomic symptom profile (ASP). Furthermore, they were inquired about quality of life (QOL, SF-36) and factors contributing to the EDS disease burden, e.g., hypermobility (5-point questionnaire, GHQ), fatigue (checklist individual strength, CIS), pain (pain detect questionnaire, PDQ), affective distress (hospital anxiety and depression scale, HADS), and physical activity (Baecke).
RESULTS: The total autonomic symptom burden was higher in EDS-HT (57.9 ± 21.57) than in controls (11.3 ± 19.22), cEDS (32.3 ± 19.47), and vEDS (29.1 ± 19.18), but comparable to FM (53.8 ± 19.85). Especially orthostatic and gastrointestinal complaints were prevalent. The importance of autonomic symptoms in EDS-HT was emphasized by the correlation with lowered QOL (r = -0.402), fatigue (r = 0.304), and pain severity (r = 0.370). Although affective distress and decreased physical activity are often suggested as possible causes for dysautonomia, the ASP did not correlate with the HADS and Baecke score. By contrast, the correlation of the GHQ (r = 0.298) and PDQ (r = 0.413) with the ASP supports the hypothesis that joint hypermobility and neuropathy may play a role in the development of autonomic symptoms.
CONCLUSION: Autonomic symptoms, especially orthostatic and gastrointestinal complaints, are frequent extraarticular manifestations of EDS-HT and contribute to the disease burden.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autonomic symptoms; Dysautonomia; Ehlers–Danlos syndrome; Fatigue; Hypermobility; Pain; Quality of life

Mesh:

Year:  2014        PMID: 24968706     DOI: 10.1016/j.semarthrit.2014.05.013

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  20 in total

1.  Systemic manifestations of Ehlers-Danlos syndrome.

Authors:  Bo Song; Peter Yeh; John Harrell
Journal:  Proc (Bayl Univ Med Cent)       Date:  2020-08-26

2.  Factors affecting quality of life in children and adolescents with hypermobile Ehlers-Danlos syndrome/hypermobility spectrum disorders.

Authors:  Weiyi Mu; Michael Muriello; Julia L Clemens; You Wang; Christy H Smith; Phuong T Tran; Peter C Rowe; Clair A Francomano; Antonie D Kline; Joann Bodurtha
Journal:  Am J Med Genet A       Date:  2019-01-31       Impact factor: 2.802

Review 3.  Current Diagnosis and Treatment of Painful Small Fiber Neuropathy.

Authors:  Khosro Farhad
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

Review 4.  Postural Tachycardia Syndrome: Beyond Orthostatic Intolerance.

Authors:  Emily M Garland; Jorge E Celedonio; Satish R Raj
Journal:  Curr Neurol Neurosci Rep       Date:  2015-09       Impact factor: 5.081

5.  Societal participation in ehlers-danlos syndromes and hypermobility spectrum disorder, compared to fibromyalgia and healthy controls.

Authors:  Stijn De Baets; Ellen Cruyt; Patrick Calders; Inge Dewandele; Fransiska Malfait; Guy Vanderstraeten; Geert Van Hove; Dominique van De Velde
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

Review 6.  Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Diagnosis and Management in Young People: A Primer.

Authors:  Peter C Rowe; Rosemary A Underhill; Kenneth J Friedman; Alan Gurwitt; Marvin S Medow; Malcolm S Schwartz; Nigel Speight; Julian M Stewart; Rosamund Vallings; Katherine S Rowe
Journal:  Front Pediatr       Date:  2017-06-19       Impact factor: 3.418

7.  Small fiber neuropathy is a common feature of Ehlers-Danlos syndromes.

Authors:  Daniele Cazzato; Marco Castori; Raffaella Lombardi; Francesca Caravello; Eleonora Dalla Bella; Antonio Petrucci; Paola Grammatico; Chiara Dordoni; Marina Colombi; Giuseppe Lauria
Journal:  Neurology       Date:  2016-06-15       Impact factor: 9.910

8.  Are patients with hypermobile Ehlers-Danlos syndrome or hypermobility spectrum disorder so different?

Authors:  Bérengère Aubry-Rozier; Adrien Schwitzguebel; Flore Valerio; Joelle Tanniger; Célia Paquier; Chantal Berna; Thomas Hügle; Charles Benaim
Journal:  Rheumatol Int       Date:  2021-08-16       Impact factor: 2.631

Review 9.  Chronic pain in hypermobility syndrome and Ehlers-Danlos syndrome (hypermobility type): it is a challenge.

Authors:  Mark C Scheper; Janneke E de Vries; Jeanine Verbunt; Raoul Hh Engelbert
Journal:  J Pain Res       Date:  2015-08-20       Impact factor: 3.133

10.  Transcriptome-Wide Expression Profiling in Skin Fibroblasts of Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome Hypermobility Type.

Authors:  Nicola Chiarelli; Giulia Carini; Nicoletta Zoppi; Chiara Dordoni; Marco Ritelli; Marina Venturini; Marco Castori; Marina Colombi
Journal:  PLoS One       Date:  2016-08-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.